1,556 results match your criteria Cardiovascular Diabetology[Journal]


GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.

Cardiovasc Diabetol 2018 Dec 13;17(1):157. Epub 2018 Dec 13.

Cardiology Division, Pontifical Catholic University of Campinas Medicine School, Rua Engenheiro Carlos Stevenson 560, Campinas, Sao Paulo, 13092-132, Brazil.

Patients with type 2 diabetes (T2DM) have a substantial risk of developing cardiovascular disease. The strong connection between the severity of hyperglycaemia, metabolic changes secondary to T2DM and vascular damage increases the risk of macrovascular complications. There is a challenging demand for the development of drugs that control hyperglycaemia and influence other metabolic risk factors to improve cardiovascular outcomes such as cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina and heart failure (major adverse cardiovascular events). Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0800-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292070PMC
December 2018
1 Read

Associations between epicardial adipose tissue, subclinical atherosclerosis and high-density lipoprotein composition in type 1 diabetes.

Cardiovasc Diabetol 2018 Dec 7;17(1):156. Epub 2018 Dec 7.

Cardiovascular Biochemistry Group, Research Institute of the Hospital de la Santa Creu i Sant Pau (IIB Sant Pau), Barcelona, Spain.

Background: The pathophysiology of cardiovascular complications in people with type 1 diabetes (T1DM) remains unclear. An increase in epicardial adipose tissue (EAT) and alterations in the composition of high-density lipoprotein (HDL) are associated with coronary artery disease, but information on its relationship in T1DM is very limited. Our aim was to determine the association between EAT volume, subclinical atherosclerosis, and HDL composition in type 1 diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0794-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284304PMC
December 2018

Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea.

Cardiovasc Diabetol 2018 Dec 5;17(1):155. Epub 2018 Dec 5.

Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 06273, Republic of Korea.

Background: Increasing evidence suggest that statin therapy has a diabetogenic effect. Individual types of statin may have a different effect on glucose metabolism. Using the repeated nationwide population-based health screening data in Korea, we investigated the longitudinal changes in fasting glucose level of non-diabetic individuals by use of statins. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0799-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280428PMC
December 2018
2 Reads

Cognitive function in adolescence and the risk for premature diabetes and cardiovascular mortality in adulthood.

Cardiovasc Diabetol 2018 Dec 5;17(1):154. Epub 2018 Dec 5.

The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Background: Epidemiological studies have demonstrated a relationship between cognitive function in youth and the future risk of death. Less is known regarding the relationship with diabetes related death. This study assessed the relationship between cognitive function in late adolescence and the risk for diabetes, cardiovascular- (CVD) and all-cause mortality in adulthood. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0798-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280532PMC
December 2018
4 Reads

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.

Cardiovasc Diabetol 2018 Dec 3;17(1):153. Epub 2018 Dec 3.

Department of Vascular Diseases, University Medical Centre Ljubljana, Zaloška Cesta 7, 1000, Ljubljana, Slovenia.

Background: Deteriorated arterial function and high incidence of cardiovascular events characterise diabetes mellitus. Metformin and recent antidiabetic drugs, SGLT2 inhibitors, reduce cardiovascular events. We explored the possible effects of empagliflozin's effect on top of metformin treatment on endothelial function and arterial stiffness parameters in type 1 diabetes mellitus (T1DM) patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0797-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276165PMC
December 2018
1 Read

Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up.

Cardiovasc Diabetol 2018 Nov 29;17(1):152. Epub 2018 Nov 29.

Department of Medical, Surgical, Neurological, Aging and Metabolic Sciences, University of Campania "Luigi Vanvitelli", Piazza Miraglia, 2, 80138, Naples, Italy.

Objectives: We evaluate whether the thrombus aspiration (TA) before primary percutaneous coronary intervention (PPCI) may improve STEMI outcomes in hyperglycemic patients.

Background: The management of hyperglycemic patients during STEMI is unclear.

Methods: We undertook an observational cohort study of 3166 first STEMI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0795-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262961PMC
November 2018

Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery.

Cardiovasc Diabetol 2018 Nov 29;17(1):151. Epub 2018 Nov 29.

Department of Cardiac Surgery, Sheba Medical Center, Tel Hashomer, Affiliated to the Sackler School of Medicine, Tel Aviv University, 52621, Tel Aviv, Israel.

Background: Type 2 diabetes mellitus (DM) is a frequent co-morbidity among patients undergoing coronary artery bypass grafting (CABG) surgery. The aim of this study was to evaluate the impact of DM on the early- and long-term outcomes of patients who underwent isolated CABG.

Methods: We performed an observational cohort study in a large tertiary medical center over a period of 11 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0796-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264047PMC
November 2018

Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program).

Cardiovasc Diabetol 2018 Nov 28;17(1):150. Epub 2018 Nov 28.

University of Leicester, University Rd, Leicester, LE1 7RH, UK.

Background: The global prevalence of type 2 diabetes-related complications is not well described. We assessed prevalence of vascular complications at baseline in DISCOVER (NCT02322762; NCT02226822), a global, prospective, observational study program of 15,992 patients with type 2 diabetes initiating second-line therapy, conducted across 38 countries.

Methods: Patients were recruited from primary and specialist healthcare settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0787-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260731PMC
November 2018

Increased glycated albumin and decreased esRAGE levels in serum are related to negative coronary artery remodeling in patients with type 2 diabetes: an Intravascular ultrasound study.

Cardiovasc Diabetol 2018 Nov 27;17(1):149. Epub 2018 Nov 27.

Department of Cardiology, Rui Jin Hospital, Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China.

Background: Negative coronary artery remodeling is frequent in patients with diabetes, but its mechanism remains unclear. We here evaluated the association of serum levels of glycated albumin (GA) and endogenous secretory receptor for advanced glycation end products (esRAGE) with coronary artery remodeling in type 2 diabetic patients.

Methods: Serum levels of GA and esRAGE were measured and intravascular ultrasound was performed in 136 consecutive diabetic patients with 143 coronary intermediate lesions. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0792-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258438PMC
November 2018
6 Reads
4.015 Impact Factor

Does glucagon have a positive inotropic effect in the human heart?

Cardiovasc Diabetol 2018 Nov 27;17(1):148. Epub 2018 Nov 27.

Departamento de Farmacologia, Facultad de Medicina, Universidad de Murcia Facultad de Medicina, Campus de Espinardo, Espinardo, 30100, Murcia, Spain.

Glucagon is considered to exert cardiostimulant effects, most notably the enhancement of heart rate and contractility, due to the stimulation of glucagon receptors associated with Gs protein stimulation which causes adenylyl cyclase activation and the consequent increase in 3',5'-cyclic adenosine monophosphate production in the myocardium. These effects have been extensively demonstrated in experimental studies in different animal species. However, efforts to extrapolate the experimental data to patients with low cardiac output states, such as acute heart failure or cardiogenic shock, have been disappointing. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0791-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258156PMC
November 2018
6 Reads

Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project.

Cardiovasc Diabetol 2018 Nov 27;17(1):147. Epub 2018 Nov 27.

Department of Epidemiology, Beijing Anzhen Hospital, The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, 100029, China.

Background: Guidelines have classified patients with acute coronary syndrome (ACS) and diabetes as a special population, with specific sections presented for the management of these patients considering their extremely high risk. However, in China up-to-date information is lacking regarding the burden of diabetes in patients with ACS and the potential impact of diabetes status on the in-hospital outcomes of these patients. This study aims to provide updated estimation for the burden of diabetes in patients with ACS in China and to evaluate whether diabetes is still associated with excess risks of early mortality and major adverse cardiovascular and cerebrovascular events (MACCE) for ACS patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0793-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258152PMC
November 2018
4.015 Impact Factor

Polyhedrocytes in blood clots of type 2 diabetic patients with high cardiovascular risk: association with glycemia, oxidative stress and platelet activation.

Cardiovasc Diabetol 2018 Nov 22;17(1):146. Epub 2018 Nov 22.

Institute of Cardiology, Jagiellonian University Medical College, Prądnicka 80 St., Kraków, Poland.

Background: Little is known about factors that affect the composition of contracted blood clots in specific diseases. We investigated the content of polyhedral erythrocytes (polyhedrocytes) formed in blood clots and its determinants in type 2 diabetes (T2D) patients.

Methods: In 97 patients with long-standing T2D [median HbA, 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0789-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251112PMC
November 2018
4 Reads

Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?

Cardiovasc Diabetol 2018 Nov 21;17(1):145. Epub 2018 Nov 21.

Department of Endocrinology and Metabolic Diseases, Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, School of Medicine, Endocrinology and Metabolic Diseases, University of Zagreb, Zagreb, Croatia.

Cardiovascular disease (CVD) is the most significant prognostic factor in individuals with type 2 diabetes (T2D). However, a significant number of individuals may develop CVD that does not present with the classic angina-related or heart failure symptoms. In these cases, CVD may seem to be 'silent' or 'asymptomatic', but may be more accurately characterised as unrecognised diabetic cardiac impairment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0788-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247507PMC
November 2018
10 Reads

A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.

Cardiovasc Diabetol 2018 11 17;17(1):144. Epub 2018 Nov 17.

Departments of Biophysics, Faculty of Medicine, Ankara University, Ankara, Turkey.

Background: Metabolic syndrome (MetS) is a prevalent risk factor for cardiac dysfunction. Although SGLT2-inhibitors have important cardioprotective effects in hyperglycemia, their underlying mechanisms are complex and not completely understood. Therefore, we examined mechanisms of a SGLT2-inhibitor dapagliflozin (DAPA)-related cardioprotection in overweight insulin-resistant MetS-rats comparison with insulin (INSU), behind its glucose-lowering effect. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0790-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240275PMC
November 2018
4 Reads

Correlations between serum concentration of three bone-derived factors and obesity and visceral fat accumulation in a cohort of middle aged men and women.

Cardiovasc Diabetol 2018 11 13;17(1):143. Epub 2018 Nov 13.

Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Clinical Center for Diabetes; Shanghai Key Clinical Center for Metabolic Disease; Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, 600 Yishan Road, Shanghai, 200233, China.

Background: The aim of this study was to investigate the interrelationships between three bone-derived factors [serum osteocalcin (OCN), fibroblast growth factor (FGF) 23, and neutrophil gelatinase-associated lipocalin (NGAL) levels] and body fat content and distribution, in order to reveal the potential endocrine function of bone in the development of obesity.

Methods: We recruited 1179 people (aged 59.5 ± 6. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0786-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233377PMC
November 2018
4 Reads

The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity.

Cardiovasc Diabetol 2018 11 8;17(1):142. Epub 2018 Nov 8.

Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, No.139, Middle Renmin Road, Changsha, 410011, Hunan, China.

Background: It is well known that angiopoietin-like protein 8 (ANGPTL8) exerts its effects on lipid metabolism through the inhibition of lipoprotein lipase and subsequent elevation of plasma triglyceride. However, it is not clear whether ANGPTL8 could affect lipid metabolism via other pathways. The study was aimed to investigate the effects of ANGPTL8 on the function of high-density lipoprotein (HDL), which plays a protective role in atherosclerosis progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0785-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223079PMC
November 2018

Platelet activity and hypercoagulation in type 2 diabetes.

Cardiovasc Diabetol 2018 11 2;17(1):141. Epub 2018 Nov 2.

Department of Physiological Sciences, Stellenbosch University, Stellenbosch Private Bag X1, Stellenbosch, 7602, South Africa.

Background: A strong correlation exists between type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD), with CVD and the presence of atherosclerosis being the prevailing cause of morbidity and mortality in diabetic populations. T2DM is accompanied by various coagulopathies, including anomalous clot formation or amyloid fibrin(ogen), the presence of dysregulated inflammatory molecules. Platelets are intimately involved in thrombus formation and particularly vulnerable to inflammatory cytokines. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0783-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214175PMC
November 2018
9 Reads

Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial.

Cardiovasc Diabetol 2018 11 1;17(1):140. Epub 2018 Nov 1.

Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, and, EA3920 and SFR-FED 4234 INSERM, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besançon, France.

Background: The aim of the study was to investigate whether intravenous (iv) infusion of exenatide, a synthetic GLP-1 receptor agonist, could provide a protective effect against myocardial ischemia-reperfusion injury after coronary artery bypass graft (CABG) surgery.

Methods: A sub study analysis of patients > 18 years admitted for elective CABG and included in the ExSTRESS trial was conducted. Patients were randomized to receive either iv exenatide (1-h bolus of 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0784-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211400PMC
November 2018
1 Read

Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study.

Cardiovasc Diabetol 2018 10 30;17(1):139. Epub 2018 Oct 30.

Department of Radiology, Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, National Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University, 20# South Renmin Road, Chengdu, Sichuan, 610041, China.

Background: Early detection of subclinical myocardial dysfunction in patients with diabetes mellitus (DM) is essential for recommending therapeutic interventions that can prevent or reverse heart failure, thereby improving the prognosis in such patients. This study aims to quantitatively evaluate left ventricular (LV) myocardial deformation and perfusion using cardiovascular magnetic resonance (CMR) imaging in patients with type 2 diabetes mellitus (T2DM), and to investigate the association between LV subclinical myocardial dysfunction and coronary microvascular perfusion.

Methods: We recruited 71 T2DM patients and 30 healthy individuals as controls who underwent CMR examination. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0782-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206833PMC
October 2018
3 Reads

Lower extremity arterial disease in patients with diabetes: a contemporary narrative review.

Cardiovasc Diabetol 2018 10 23;17(1):138. Epub 2018 Oct 23.

Département d'Endocrinologie, Diabétologie, Nutrition, Hôpital Haut-Lévêque, Avenue de Magellan, 33604, Pessac Cedex, France.

Lower-extremity arterial disease (LEAD) is a major endemic disease with an alarming increased prevalence worldwide. It is a common and severe condition with excess risk of major cardiovascular events and death. It also leads to a high rate of lower-limb adverse events and non-traumatic amputation. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0781-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198374PMC
October 2018
5 Reads

Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.

Cardiovasc Diabetol 2018 10 22;17(1):137. Epub 2018 Oct 22.

Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania "Luigi Vanvitelli", Piazza Miraglia, 2, 80138, Naples, Italy.

Objectives: To evaluate clinical outcomes in patients with diabetes, treated by cardiac resynchronization therapy with a defibrillator (CRT-d), and glucagon-like peptide 1 receptor agonists (GLP-1 RA) in addition to conventional hypoglycemic therapy vs. CRTd patients under conventional hypoglycemic drugs.

Background: Patients with diabetes treated by CRTd experienced an amelioration of functional New York Association Heart class, reduction of hospital admissions, and mortality, in a percentage about 60%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0778-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196445PMC
October 2018
1 Read

Hyperglycemia and risk of ventricular tachycardia among patients hospitalized with acute myocardial infarction.

Cardiovasc Diabetol 2018 10 19;17(1):136. Epub 2018 Oct 19.

Department of Quantitative Health Sciences, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA, 01605, USA.

Background: Little is known about the association of hyperglycemia with the development of ventricular tachycardia (VT) in patients hospitalized with acute myocardial infarction (AMI) which we examined in the present study. The objectives of this community-wide observational study were to examine the relation between elevated serum glucose levels at the time of hospital admission for AMI and occurrence of VT, and time of occurrence of VT, during the patient's acute hospitalization.

Methods: We used data from a population-based study of patients hospitalized with AMI at all central Massachusetts medical centers between 2001 and 2011. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0779-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194566PMC
October 2018

Impact of type 2 diabetes mellitus in the utilization and in-hospital outcomes of surgical aortic valve replacement in Spain (2001-2015).

Cardiovasc Diabetol 2018 10 16;17(1):135. Epub 2018 Oct 16.

Preventive Medicine and Public Health Teaching and Research Unit, Health Sciences Faculty, Rey Juan Carlos University, Alcorcón, Madrid, Spain.

Background: The aims of this study were to examine trends in the incidence and in-hospital outcomes of SAVR among T2DM patients from 2001 to 2015, to compare clinical variables among T2DM patients and matched non-T2DM patients hospitalized for SAVR and to identify factors associated with in-hospital mortality (IHM) among T2DM patients.

Methods: We performed a retrospective study using the Spanish National Hospital Discharge Database, 2001-2015. We included patients who had SAVR as the procedure in their discharge report. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0780-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190659PMC
October 2018

Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword.

Cardiovasc Diabetol 2018 10 10;17(1):134. Epub 2018 Oct 10.

Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, University of South China, Hengyang, 421001, China.

Perivascular adipose tissue (PVAT), the adipose tissue that surrounds most of the vasculature, has emerged as an active component of the blood vessel wall regulating vascular homeostasis and affecting the pathogenesis of atherosclerosis. Although PVAT characteristics resemble both brown and white adipose tissues, recent evidence suggests that PVAT develops from its own distinct precursors implying a closer link between PVAT and vascular system. Under physiological conditions, PVAT has potent anti-atherogenic properties mediated by its ability to secrete various biologically active factors that induce non-shivering thermogenesis and metabolize fatty acids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0777-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180425PMC
October 2018

Rising plasminogen activator inhibitor-1 and hypoadiponectinemia characterize the cardiometabolic biomarker profile of women with recent gestational diabetes.

Cardiovasc Diabetol 2018 10 9;17(1):133. Epub 2018 Oct 9.

Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, 60 Murray Street, Suite-L5-039, Mailbox-21, Toronto, ON, M5T3L9, Canada.

Background: Gestational diabetes (GDM) and milder gestational impaired glucose tolerance (GIGT) identify women at risk of developing type 2 diabetes and cardiovascular disease later in life. Accordingly, the postpartum years after gestational dysglycemia can provide insight into early events in the natural history of these disorders. We thus sought to prospectively evaluate the relationship between gestational glucose tolerance and emerging cardiometabolic biomarkers [adiponectin, chemerin, retinol-binding protein-4 (RBP-4), C-reactive protein (CRP), plasminogen activator inhibitor-1 (PAI-1)] at both 1- and 3-years postpartum in a cohort reflecting the full spectrum of gestational dysglycemia (from normal to GIGT to GDM). Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0776-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176527PMC
October 2018
7 Reads

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.

Cardiovasc Diabetol 2018 10 8;17(1):132. Epub 2018 Oct 8.

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

Background: The objective of this study was to investigate the impact of sodium glucose cotransporter type 2 (SGLT2) inhibitors on left ventricular (LV) diastolic function of type 2 diabetes mellitus (T2DM) patients with heart failure (HF).

Methods: This trial was a prospective multicenter study of 58 T2DM patients with stable HF at five institutions in Japan. Patients who had been taking at least one antidiabetic drugs other than SGLT2 inhibitors started the administration of 5 mg/day of dapagliflozin. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0775-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174555PMC
October 2018
1 Read

Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting.

Cardiovasc Diabetol 2018 09 29;17(1):131. Epub 2018 Sep 29.

Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Background: As a strong platelet agonist on the one hand and key molecule in plasmatic coagulation on the other hand, thrombin connects primary and secondary hemostasis. Thrombin generation potential reflects the individual capacity to generate thrombin, and has been associated with the occurrence of thromboembolic events. In the current study, we sought to identify predictors of thrombin generation potential in patients undergoing angioplasty and stenting for atherosclerotic cardiovascular disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0774-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162876PMC
September 2018
1 Read

Both pre-frailty and frailty increase healthcare utilization and adverse health outcomes in patients with type 2 diabetes mellitus.

Cardiovasc Diabetol 2018 09 27;17(1):130. Epub 2018 Sep 27.

Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei, 10617, Taiwan.

Background: Diabetes mellitus (DM) correlates with accelerated aging and earlier appearance of geriatric phenotypes, including frailty. However, whether pre-frailty or frailty predicts greater healthcare utilization in diabetes patients is unclear.

Methods: From the Longitudinal Cohort of Diabetes Patients in Taiwan (n = 840,000) between 2004 and 2010, we identified 560,795 patients with incident type 2 DM, categorized into patients without frailty, or with 1, 2 (pre-frail) and ≥ 3 frailty components, based on FRAIL scale (Fatigue, Resistance, Ambulation, Illness, and body weight Loss). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0772-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158921PMC
September 2018
9 Reads

Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis.

Cardiovasc Diabetol 2018 09 27;17(1):129. Epub 2018 Sep 27.

Department of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-2, Funae, 1-chome, Ise-shi, Mie, 516-8512, Japan.

Background: We used a network meta-analysis of randomized controlled trials (RCTs) to comparatively examine the effects of oral antidiabetic drugs (OADs) on left ventricular mass (LVM) in patients with type 2 diabetes.

Methods: Document searches were implemented using Medline, Cochrane Controlled Trials Registry, and ClinicalTrials.gov. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0773-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158875PMC
September 2018
1 Read

Early vascular parameters in the micro- and macrocirculation in type 2 diabetes.

Cardiovasc Diabetol 2018 09 19;17(1):128. Epub 2018 Sep 19.

Department of Nephrology and Hypertension, University Hospital of the University of Erlangen-Nuremberg, Ulmenweg 18, 91054, Erlangen, Germany.

Background: Diabetes converts from a metabolic disorder into a predominantly vascular disease, once its duration extends over several years or/and when additional cardiovascular risk factors such as hypertension coexist. In a cross-sectional analysis we analyzed various vascular parameters in the renal, retinal and systemic circulation, with the goal to identify which vascular parameter of early organ damage is the earliest that can be clinically detected.

Methods: In 111 patients with type 2 diabetes (T2DM) (off any anti-diabetic medication for at least 4 weeks) and 54 subjects without T2DM we compared various parameters of early vascular remodeling in the same patient: urinary albumin creatinine ratio ([UACR], early morning spot urine) and estimated glomerular filtration rate (eGFR), retinal capillary flow (RCF) and intercapillary distance (ICD) as parameters of capillary rarefaction, wall-to-lumen ratio (WLR) of the retinal arterioles [all assessed by Scanning Laser Doppler Flowmetry], and central systolic pressure (cSBP) and central pulse pressure (cPP) [measured by pulse wave analysis, Syphygmocor] both reflecting vascular stiffness of large arteries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0770-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146516PMC
September 2018

ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus.

Cardiovasc Diabetol 2018 09 18;17(1):127. Epub 2018 Sep 18.

Department of Cardiology, Shufu People's Hospital, Kashgar Region, Xinjiang Uygur Autonomous Region (XUAR), 844100, China.

Background: Type 2 diabetes mellitus (T2D), rapidly increasing to epidemic proportions, globally escalates cardiovascular disease risk. Although intensive interventions and comprehensive management of environmental risks factors for T2D are associated with reduced cardiovascular disease, such approaches are limited for individuals with high genetic T2D risk. In this study we investigated possible associations of ACE2 polymorphisms and cardiovascular risks in Uygur patients with T2D. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0771-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142339PMC
September 2018
1 Read

The role of physical activity in the development of first cardiovascular disease event: a tree-structured survival analysis of the Danish ADDITION-PRO cohort.

Cardiovasc Diabetol 2018 09 12;17(1):126. Epub 2018 Sep 12.

Clinical Epidemiology, Steno Diabetes Center Copenhagen, Niels Steensens Vej 2-6, 2820, Gentofte, Capital Region, Denmark.

Background: Ambiguity exists in relation to the role of physical activity (PA) for cardiovascular disease (CVD) risk reduction. We examined the interplay between PA dimensions and more conventional CVD risk factors to assess which PA dimensions were associated with the first CVD event and whether subgroup differences exist.

Methods: A total of 1449 individuals [median age 65. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0769-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134699PMC
September 2018
2 Reads

Midlife development of type 2 diabetes and hypertension in women by history of hypertensive disorders of pregnancy.

Cardiovasc Diabetol 2018 09 10;17(1):124. Epub 2018 Sep 10.

Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Background: Women with history of hypertensive disorders of pregnancy (HDP) are at increased risk of early onset cardiovascular disease and type 2 diabetes (T2D). We aimed to investigate the extent to which HDP is also associated with midlife development of T2D and hypertension above and beyond established risk factors.

Methods: We included parous women who attended population-based structured clinical visits at age 50 and 60 years in Sweden 1991-2013 (N = 6587). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0764-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130069PMC
September 2018
1 Read

Type 2 diabetes is independently associated with all-cause mortality secondary to ventricular tachyarrhythmias.

Cardiovasc Diabetol 2018 09 10;17(1):125. Epub 2018 Sep 10.

First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Objectives: The study sought to assess the prognostic impact of type 2 diabetes in patients presenting with ventricular tachyarrhythmias on admission.

Background: Data regarding the prognostic outcome of diabetics presenting with ventricular tachyarrhythmias is limited.

Methods: A large retrospective registry was used including all consecutive patients presenting with ventricular tachycardia (VT) and fibrillation (VF) on admission from 2002 to 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0768-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130079PMC
September 2018
2 Reads

MiR-21 protected against diabetic cardiomyopathy induced diastolic dysfunction by targeting gelsolin.

Cardiovasc Diabetol 2018 09 4;17(1):123. Epub 2018 Sep 4.

Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave., Wuhan, 430030, China.

Background: Diabetes is a leading cause of mortality and morbidity across the world. Over 50% of deaths among diabetic patients are caused by cardiovascular diseases. Cardiac diastolic dysfunction is one of the key early signs of diabetic cardiomyopathy, which often occurs before systolic dysfunction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0767-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122727PMC
September 2018
6 Reads

Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies.

Cardiovasc Diabetol 2018 08 31;17(1):121. Epub 2018 Aug 31.

Department of Molecular Biology & Biochemistry, Guru Nanak Dev University, Amritsar, Punjab, India.

The incidence and prevalence of diabetes mellitus is rapidly increasing worldwide at an alarming rate. Type 2 diabetes mellitus (T2DM) is the most prevalent form of diabetes, accounting for approximately 90-95% of the total diabetes cases worldwide. Besides affecting the ability of body to use glucose, it is associated with micro-vascular and macro-vascular complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0763-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117983PMC

Association between insulin resistance and the development of cardiovascular disease.

Cardiovasc Diabetol 2018 08 31;17(1):122. Epub 2018 Aug 31.

Faculty of Pharmacy, Department of Clinical Biochemistry and Immunology, University of Concepcion, Concepción, Chile.

For many years, cardiovascular disease (CVD) has been the leading cause of death around the world. Often associated with CVD are comorbidities such as obesity, abnormal lipid profiles and insulin resistance. Insulin is a key hormone that functions as a regulator of cellular metabolism in many tissues in the human body. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0762-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119242PMC
August 2018
9 Reads

Metabolomic profiling implicates adiponectin as mediator of a favorable lipoprotein profile associated with NT-proBNP.

Cardiovasc Diabetol 2018 08 28;17(1):120. Epub 2018 Aug 28.

Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Str, 17475, Greifswald, Germany.

Background: The N-terminal prohormone of brain natriuretic peptide (NT-proBNP) is an important biomarker for the diagnosis of heart failure. Apart from this and only recently recognized, NT-proBNP levels associate with higher HDL- and lower LDL-cholesterol levels comprising a favorable blood lipid profile. To further examine this observation, the lipoprotein profile in relation to NT-proBNP was examined in-depth by proton nuclear magnetic resonance spectroscopy (H-NMR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0765-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112131PMC
August 2018
1 Read

Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter?

Cardiovasc Diabetol 2018 08 28;17(1):119. Epub 2018 Aug 28.

Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.

There is a vast disagreement in relation to the possible beneficial effects of omega-3 polyunsaturated fatty acids (omega-3 PUFA) supplementation in patients with diabetes and cardiovascular disease. The conflicting results between the various original studies and meta-analyses could be partially explained as a result of variable supplementation dosage and duration, either of which may modify the effects of omega-3 PUFA on cardio-metabolic biomarkers. Meta-analyses are limited usually by the inability to draw inferences regarding dosage, duration and the interaction of dosage and duration of omega-3 PUFA intake. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0766-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112138PMC
August 2018
7 Reads

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.

Cardiovasc Diabetol 2018 08 24;17(1):118. Epub 2018 Aug 24.

Rockwood Clinic, Spokane, WA, USA.

Background: There exist several predictive risk models for cardiovascular disease (CVD), including some developed specifically for patients with type 2 diabetes mellitus (T2DM). However, the models developed for a diabetic population are based on information derived from medical records or laboratory results, which are not typically available to entities like payers or quality of care organizations. The objective of this study is to develop and validate models predicting the risk of cardiovascular events in patients with T2DM based on medical insurance claims data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0759-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109303PMC
August 2018
8 Reads

Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.

Cardiovasc Diabetol 2018 08 22;17(1):117. Epub 2018 Aug 22.

Institute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, HaAliya HaShniya Street 8, 3109601, Haifa, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0760-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103874PMC
August 2018
1 Read

Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome.

Cardiovasc Diabetol 2018 08 18;17(1):116. Epub 2018 Aug 18.

Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.

Background: Impaired glucose metabolism is an established risk factor for coronary artery disease. Previous studies revealed that glycemic variability (GV) is also important for glucose metabolism in patients with acute coronary syndrome (ACS). We explored the association between GV and prognosis in patients with ACS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0761-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098663PMC
August 2018
1 Read

Correction to: Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving 'SIRT1 and PGC-1α'.

Cardiovasc Diabetol 2018 08 17;17(1):115. Epub 2018 Aug 17.

Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Unfortunately, after publication of this article [1], it was noticed that Table 1 contained errors introduced during the production process. In the WT + AT column, the FS value is 21 ± 7 and the Body Weight value is 25 ± 2. In the WT + AT + CR column, the FS value is 46 ± 14 and the Body Weight value is 19 ± 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0757-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097296PMC
August 2018
7 Reads

Overweight and obesity impair left ventricular systolic function as measured by left ventricular ejection fraction and global longitudinal strain.

Cardiovasc Diabetol 2018 08 14;17(1):113. Epub 2018 Aug 14.

Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.

Aims: Obesity is associated with type 2 diabetes mellitus, left ventricular diastolic dysfunction and heart failure but it is unclear to which extent it is related to left ventricular systolic dysfunction. The aim of the study was to explore the effects of overweight and obesity on left ventricular systolic function in patients with type 2 diabetes mellitus and a control group of non-diabetic persons.

Methods: We prospectively investigated 384 patients with type 2 diabetes mellitus, and 184 controls who participated in the CARDIPP and CAREFUL studies. Read More

View Article

Download full-text PDF

Source
https://cardiab.biomedcentral.com/articles/10.1186/s12933-01
Publisher Site
http://dx.doi.org/10.1186/s12933-018-0756-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090791PMC
August 2018
8 Reads
4.015 Impact Factor

Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study.

Cardiovasc Diabetol 2018 08 14;17(1):114. Epub 2018 Aug 14.

State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Centre for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beilishi Road 167, Xicheng District, Beijing, Postal code: 100037, China.

Background: To improve outcomes in patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention remain an unmet clinical need. The study aimed to evaluate the efficacy and safety of G2-DESs and BP-DESs in patients with and without DM in a single center in China.

Methods: A total of 7666 consecutive patients who exclusively had G2-DES or BP-DES implantation throughout 2013 in our center were studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0758-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090623PMC
August 2018
11 Reads

Low muscle quality in Japanese type 2 diabetic patients with visceral fat accumulation.

Cardiovasc Diabetol 2018 08 4;17(1):112. Epub 2018 Aug 4.

Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2 B-5, Yamada-oka, Suita, Osaka, 565-0871, Japan.

Background: Although obesity-related type 2 diabetes mellitus (T2DM) and sarcopenia in the elderly have been increasing worldwide, the associations among visceral fat accumulation, skeletal muscle indices (mass, strength, and quality) and cardiovascular diseases in T2DM remain poorly investigated.

Methods: We enrolled 183 Japanese T2DM inpatients (126 men, 57 women; mean age 64.7 ± 12. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0755-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076400PMC
August 2018
11 Reads

Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes.

Cardiovasc Diabetol 2018 08 2;17(1):110. Epub 2018 Aug 2.

INSERM, UMRS 1138, Centre de Recherche des Cordeliers, 15 rue de l'École de Médecine, Paris, 75006, France.

Background: Cardiovascular disease and kidney damage are tightly associated in people with type 2 diabetes. Experimental evidence supports a causal role for vasopressin (or antidiuretic hormone) in the development of diabetic kidney disease (DKD). Plasma copeptin, the COOH-terminal portion of pre-provasopressin and a surrogate marker of vasopressin, was shown to be positively associated with the development and progression of DKD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0753-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071392PMC

Progression of cardiovascular autonomic neuropathy and cardiovascular disease in type 2 diabetes.

Cardiovasc Diabetol 2018 08 2;17(1):109. Epub 2018 Aug 2.

Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Ji-dong, Paldal-gu, Suwon, 16247, South Korea.

Background: To examine whether the progression rate of cardiovascular autonomic neuropathy (CAN) stage is an independent predictive factor for cardiovascular disease (CVD) in type 2 diabetes.

Methods: Standardized cardiovascular autonomic reflex tests (CARTs) using traditional Ewing method were performed at baseline. The follow-up CARTs was recommended once every two years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0752-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071370PMC
August 2018
2 Reads
4.010 Impact Factor

Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving 'SIRT1 and PGC-1α'.

Cardiovasc Diabetol 2018 08 2;17(1):111. Epub 2018 Aug 2.

Cardiac Research Laboratory, Felsenstein Medical Research Institute Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Background: Metabolic disorders such as obesity, insulin resistance and type 2 diabetes mellitus (DM2) are all linked to diabetic cardiomyopathy that lead to heart failure. Cardiomyopathy is initially characterized by cardiomyocyte hypertrophy, followed by mitochondrial dysfunction and fibrosis, both of which are aggravated by angiotensin. Caloric restriction (CR) is cardioprotective in animal models of heart disease through its catabolic activity and activation of the expression of adaptive genes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0754-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090985PMC
August 2018
10 Reads

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.

Cardiovasc Diabetol 2018 07 30;17(1):108. Epub 2018 Jul 30.

Diabetes and Cardiovascular Center, University of Missouri School of Medicine, Columbia, MO, USA.

Background: Arterial stiffness is emerging as an independent risk factor for the development of chronic kidney disease. The sodium glucose co-transporter 2 (SGLT2) inhibitors, which lower serum glucose by inhibiting SGLT2-mediated glucose reabsorption in renal proximal tubules, have shown promise in reducing arterial stiffness and the risk of cardiovascular and kidney disease in individuals with type 2 diabetes mellitus. Since hyperglycemia contributes to arterial stiffness, we hypothesized that the SGLT2 inhibitor empagliflozin (EMPA) would improve endothelial function, reduce aortic stiffness, and attenuate kidney disease by lowering hyperglycemia in type 2 diabetic female mice (db/db). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12933-018-0750-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065158PMC
July 2018
2 Reads